Enliven Therapeutics’ ELVN-001 Delivers Strong Results in Phase 1 CML Study, Aligns with FDA on Phase 3 Design
Early results show performance that is comparable to a widely used Novartis blockbuster and a Merck-owned experimental treatment.
/ 5 items
#ELVN↓
Why Merck’s Big CML Bet Makes Enliven’s ELVN-001 a Takeover Star
Merck’s $6.7B acquisition of Terns Pharmaceuticals highlights huge potential in CML therapies. Why analysts see Enliven’s ELVN-001 as a best-in-class winner with strong takeover appeal.
Merck Buys Terns Pharmaceuticals for $6.7 Billion to Boost Blood Cancer Pipeline with Promising CML Drug
Merck is buying Terns Pharmaceuticals for $6.7 billion to add TERN-701, a promising new oral drug for chronic myeloid leukemia (CML). The move strengthens its cancer pipeline as Keytruda patent expiry nears in 2028.
ELVN-001 Shows 69% Response Rate in CML Phase 1b Trial Results
Enliven Therapeutics (ELVN) reports encouraging Phase 1b results for ELVN-001, a new treatment for chronic myeloid leukemia, with strong response rates and excellent safety profile.
William Blair Upgrades Terns Pharmaceuticals to Outperform After Strong TERN-701 Data
William Blair upgraded Terns Pharmaceuticals (TERN) to Outperform following impressive Phase 1 CARDINAL trial results of TERN-701 in chronic myeloid leukemia, showing a 75% overall major molecular response rate and strong safety profile.